Journal article icon

Journal article

Systematic review: the safety of vedolizumab for the treatment of inflammatory bowel disease.

Abstract:

Background

Vedolizumab specifically recognizes the 47 integrin and selectively blocks gut lymphocyte trafficking: potentially, it offers gut-specific immunosuppression.

Aims

To review the safety of vedolizumab and summarise post-marketing data to assess if any safety concerns that differ from registration trials have emerged.

Method

A systematic bibliographic search identified six registration trials and nine cohort studies.

Results

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Accepted manuscript

Actions


Access Document


Files:
Publisher copy:
10.1111/apt.14075

Authors


Jairath, V More by this author
More by this author
Department:
Linacre College
Publisher:
Wiley Publisher's website
Journal:
Alimentary Pharmacology and Therapy Journal website
Volume:
46
Issue:
1
Pages:
3-15
Publication date:
2017-04-27
Acceptance date:
2017-03-13
DOI:
ISSN:
1365-2036
Pubs id:
pubs:692411
URN:
uri:17413ebd-cec0-46b5-9673-2ca222813320
UUID:
uuid:17413ebd-cec0-46b5-9673-2ca222813320
Local pid:
pubs:692411

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP